TD Cowen Reiterates Buy Rating on Ginkgo Bioworks Holdings Inc (DNA)

TD Cowen analyst Steven Mah reiterated a Buy rating and $3.00 price target on Ginkgo Bioworks Holdings Inc (NYSE: DNA).

The analyst commented, "Promising addition to Google Cloud partnership expands access to DNA's AI interface to further democratize AI-driven drug discovery. New protein LLM provides access to DNA's proprietary database to unlock protein interactions + optimize leads. New open API expands access to AI tools more broadly. We expect additional partnerships + product rollouts should continue to bolster DNA's AI toolbox."

For an analyst ratings summary and ratings history on Ginkgo Bioworks Holdings Inc click here. For more ratings news on Ginkgo Bioworks Holdings Inc click here.

Shares of Ginkgo Bioworks Holdings Inc closed at $6.23 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• AI/ML Innovations plans $2M private placement on the CSE
• Mosaic sets pricing for tender offers on up to $1.4B in debt